INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic renal disease with a prevalence of 1:1,000 births and it is the 4th most common cause of dialysis-dependent end-stage renal disease (ESDR). Recent reports suggest an association between APDKD and metabolic derangements, particularly impaired glucose metabolism. METHODS: In this cross-sectional study we analyzed data obtained from case records of 189 patients with ADPKD, including kidney transplant recipients, managed in an outpatient department. RESULTS: The mean BMI was 25.4 ± 3.9; 25.25 before and 27.7 after transplan-tation. A fasting glucose level above 100 mg/dL (5.6 mmol/L) was observed in 60 patients (29%) - 27% without transplantation and 41% kidney transplant recipients. Diabetes mellitus was diagnosed in 17 patients (8.9%), including 3 (2.3%) without a history of transplantation and 14 (24.1%) after kidney transplantation (p < 0.01). We observed dyslipidemia in 30% and hyperuricemia in 53% of patients. CONCLUSION: Demonstrated metabolic abnormalities should be considered in maintenance of ADPKD patients, including kidney transplant recipients.
No takes yet. Share an insight, caveat, or question.
Fliszkiewicz et al. (2019) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: